Companies are developing myostatin inhibitors for GLP-1RA- related muscle loss, but some experts doubt their necessity.

Q1 2025 Earnings Call Transcript April 29, 2025 Regeneron Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS ...

In 2023, the myotonic dystrophy treatment market is projected to be worth USD 874.39 million. The global demand for myotonic dystrophy treatment is anticipated to increase at a CAGR of 12.3% between ...

Scholar Rock Holding Corporation’s SRRK share price has dipped by 5.79%, which has investors questioning if this is right ...

Few supplements have sparked as much debate in gyms and science labs as creatine. In a recent video, Dr. Mike Israetel tackled a new study that questions ...

Our unique mechanism of action provides more complete C5 inhibition than observed with other C5 approaches that are approved in this indication, as well as the potential for more convenient ...

Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth ... of the activation of myostatin that is in Phase 3 clinical ...

Mechanisms and PharmacologyTuesday 4/8/25 11:45am-12:45pm Incorporating Patient Perspectives into a Composite Score for Measuring Disease Progression in Spinocerebellar Ataxia (SCA)P12 ...